Reactivation of HIV-1 gene expression to treat persistent HIV infection

Université Libre de Bruxelles - Réseau LIEU - 09/18/2020

Description

The combined use of two drugs to activate latent HIV could cause a synergistic reactivation of HIV-1 production. Indeed, a proof-of-concept has been demonstrated by inventors for the coadministration of two different types of therapeutically promising HIV-1 inducers [DNA methylation inhibitors in combination with histone deacethylase inhibitors (HDACis) or histone methyltransferase inhibitors (HMTis) in combination with HDACi or NF-kappaB inducers] together with efficient cART as a therapeutic perspective to decrease the pool of latent HIV-1 reservoirs.

Benefits

Obtaining a regimen to eliminate the latent compartment of HIV-1 and stop cART therapies may: - limit exposure to the anti-AIDS molecules, thereby limiting side effects → the life quality of the patients would be greatly improved. - reduce the care costs for HIV+ patients.

Innovations

New drug combination with efficient cART used as a therapeutic perspective to decrease latent HIV-1. As selected molecules are already promising candidates or accepted in human clinical trials or therapies for other diseases, a clinical phase Ib/II has been launched. The cART therapy is the only treatment currently available for AIDS and our current approach is innovative, no competition exists for the moment in this competitive market.

Sheet PDF